General form of registration statement for all companies including face-amount certificate companies

INTELLECTUAL PROPERTY/ LICENSING RIGHTS (Details Narrative)

v3.10.0.1
INTELLECTUAL PROPERTY/ LICENSING RIGHTS (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Oct. 12, 2018
Oct. 01, 2015
Jul. 28, 2016
Jan. 26, 2016
Jun. 30, 2015
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2017
Dec. 31, 2016
Termination of licensing agreement                   $ 132,804
Intellectual property fees       $ 55,648              
Description for right to purchase perpetual rights       North America with the option for Central and South America for Naltrexone Implants formulas created by the Seller for 24 months upon receipt of the intellectual property for a fee of $55,648. The Company, within the first 12 months has the right to purchase perpetual rights for above territories for a one-time fee, financed over 5 years. The rights are amortized over the 24 month contract life.              
Amortization expenses           $ 0 $ 7,013 $ 1,963 $ 20,810 $ 27,767 25,918
Agreement description                   On March 31, 2016, the parties agreed to terminate the above described acquisition and to cancel any and all obligations assumed under the agreement.  
Naltrexone Implant Formulation [Member]                      
Aggregate purchase price         $ 1,132,000           1,132,000
Estimated useful life         10 years            
Purchase obligation to pay         $ 1,000,000            
Acquired rights, title and interest payment period   14 months                  
Common stock shares issued upon acquisition of rights         30,000            
Share price         $ 4.40            
Therakine, Ltd. [Member]                      
License cost     $ 2,750,000                
Aggregate purchase price     $ 250,000         $ 250,000   $ 250,000 250,000
Escrow deposit                   $ 75,000 $ 75,000
Subsequent Event [Member] | Therakine Biodelivery GmbH [Member]                      
Patent acquired $ 15,200                    
Development, Commerialization and License agreement, description Patent families consisting of approximately 11 patents pending and 1 issued patent.